Wolverine stack vs Glow protocol

Comparison 7 min read Reviewed

Two of the most popular peptide stacks on TikTok, compared: compounds, mechanisms, timelines, and who each one is typically used by.

Contents9
  1. 1Where the names come from
  2. 2The Wolverine stack: BPC-157 + TB-500
  3. 3The Glow protocol: BPC-157 + TB-500 + GHK-Cu
  4. 4Side-by-side comparison
  5. 5Week-by-week timeline: what to expect
  6. 6Can you combine them? The full three-compound stack
  7. 7Tracking a multi-compound stack
  8. 8Frequently asked questions
  9. 9References

The Wolverine Stack and the Glow Protocol are two of the most discussed healing peptide combinations in online peptide communities. This page sets out what each contains, what the research on each part shows, and how they differ.

The short version: the Wolverine Stack is BPC-157 + TB-500, aimed at injury recovery and tissue repair. The Glow Protocol is the same two compounds with GHK-Cu added, aimed also at skin. The Glow Protocol is the Wolverine Stack plus one compound.

Where the names come from

Neither "Wolverine Stack" nor "Glow Protocol" is a clinical or scientific name. Both come from online peptide and biohacking communities; the Wolverine name refers to the Marvel character's healing.

These are community names, not standard formulations, and sources describe different compounds and doses under them. What follows is the most commonly described version.

The Wolverine stack: BPC-157 + TB-500

Wolverine stack

Recovery Focus

Stated goal: injury recovery, joint and tendon support, gut healing, athletic tissue repair.

Who it is discussed by: athletes with lingering injuries, people recovering from surgery, people with chronic joint or tendon problems.

Typical duration: community protocols often run a finite 8-12 weeks. No human trial of this combination, or of its duration, was found.1

BPC-157: the anchor compound

BPC-157 is described as a naturally occurring gastric peptide that promotes mucosal integrity. A 2025 systematic review found 36 studies from an orthopaedic sports medicine view, 35 preclinical and 1 clinical; in preclinical models it improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries.1

The same review reports studies suggesting BPC-157 enhances growth hormone receptor expression and pathways in cell growth and angiogenesis, while reducing inflammatory cytokines. Its half-life was under 30 minutes in rats and dogs, and it is metabolised in the liver and cleared by the kidneys.13 No clinical safety data were found.1

In community use, BPC-157 is injected under the skin near an injury or elsewhere for general use; nasal use is also practised. The one human study in the review used injection into the knee: 7 of 12 patients with chronic knee pain reported relief for more than 6 months.1 The FDA says compounded BPC-157 may pose a risk of immunogenicity for some routes and has only limited safety information.2

TB-500: the systemic amplifier

TB-500 is a fragment of thymosin beta-4 (LKKTETQ), by the FDA's description.2 Thymosin beta-4 itself is described as a major actin-sequestering protein studied for tissue repair, mostly in heart injury.4 The FDA says it has not identified any human exposure data for TB-500, and that it may pose an immunogenicity risk from aggregation and impurities.2

No pharmacokinetic study of TB-500 in humans was found.2 Community protocols often dose it twice weekly rather than daily.

The reasoning for combining them is that they act through different pathways. No study of the two together was found, so any combined effect is a user report, not a trial result.

The Glow protocol: BPC-157 + TB-500 + GHK-Cu

Glow protocol

Recovery + Skin + Anti-Aging

Stated goal: the Wolverine Stack goals plus skin quality, collagen, hair and wound healing.

Who it is discussed by: people with both recovery and skin goals, often following skin-focused social media content.

Typical duration: often longer than the Wolverine Stack in community protocols, 12-16 weeks, on the view that skin changes take longer. No trial of this combination was found.

GHK-Cu: the Glow addition

GHK-Cu is a copper-binding tripeptide (glycyl-histidyl-lysine). A review describes GHK as present in human plasma, saliva and urine and declining with age, which is the basis of its anti-aging appeal; it stimulates both synthesis and breakdown of collagen and glycosaminoglycans.5

For skin, the evidence in that review is largely from cosmetic products, which tightened skin and improved elasticity and density, and from wound healing in animals.5 Injectable GHK-Cu is used in community protocols for wider effects; the FDA notes limited human data on the safety of injectable GHK-Cu and a possible immunogenicity risk.2

No human pharmacokinetic study of injected GHK-Cu was found. Users report mild injection site reactions and, for some, mild fatigue at the start.

Side-by-side comparison

Factor Wolverine stack Glow protocol
Compounds BPC-157 + TB-500 GHK-Cu + BPC-157 + TB-500
Primary goal Injury recovery, joint/tendon, gut healing Recovery + skin quality, collagen, anti-aging
Daily injections 1–2 (BPC-157 daily, TB-500 2x/week) 2–3 (adds daily GHK-Cu)
Typical duration 8–12 weeks (community) 12–16 weeks (community)
Expected timeline for effects User reports only; no trial User reports only; no trial
Side effect profile No clinical safety data1 No clinical safety data; limited human data on GHK-Cu2
Vials to manage 2 3
Best for joint pain Yes, primary use case Yes, same BPC-157/TB-500 base
Best for skin Not its stated aim Yes, GHK-Cu primary driver

Week-by-week timeline: what to expect

No human timeline exists for either stack. What follows is community report, set against what the research does say. Of 36 BPC-157 studies in the 2025 review, 35 were preclinical.1

Week 1–2
Early subjective effects

Users commonly report less soreness and better recovery in the first week or two. No trial measured this. Skin effects are not reported this early.

Week 3–4
TB-500 effects becoming apparent

Users on the Glow Protocol commonly report early skin changes from around week 3, more feel than visible change. No trial measured this.

Week 4–8
Structural recovery and early skin changes

The window where users most often report improvement in joint and tendon problems, tracked by range of motion and pain on movement, and first visible skin changes on the Glow Protocol. These are user reports.

Week 8–12
Full Wolverine Stack effects

Users focused on an injury often report a plateau around weeks 10-12 and decide then whether to continue or stop. For longer-standing problems some extend to 16 weeks or more.

Week 10–16
Full Glow Protocol skin and collagen effects

Users tracking skin report the largest visible changes in weeks 10-16. The review's skin evidence comes from cosmetic products rather than injection, so these timelines are not from trials.5

Can you combine them? The full three-compound stack

Since the Glow Protocol is the Wolverine Stack with GHK-Cu added, running all three at once is the Glow Protocol itself. No interaction study of the three together was found; the absence of known interactions reflects the absence of studies.

The practical considerations of running all three are mostly logistical:

  • Three reconstituted vials to store and track. Research peptides have no approved figure for how long a mixed vial lasts; approved reconstituted products give 14 to 30 days refrigerated.867
  • Injection frequency increases: often 2-3 subcutaneous injections a day. Rotating sites across the three spreads injections out.
  • Cost rises with each compound added, by an amount that depends on sourcing.
Practical note

Some people start with the Wolverine Stack and add GHK-Cu later, once the routine is settled; others start all three at once, depending on whether skin is a goal from the start.

Tracking a multi-compound stack

Each compound in these stacks has its own clearance, so each reaches steady state on its own timeline. That matters for reading when effects might be expected and which compound is contributing.

BPC-157's half-life was under 30 minutes in rats and dogs, so it would clear quickly and a missed dose would show at once.3 No human half-life was found for TB-500 or injected GHK-Cu.2

Without dose logging, it is hard to attribute effects, side effects or lack of progress to any one compound. When things go as expected that does not matter; when they do not, it does.

Per-compound records matter even for short half-life compounds like BPC-157: not because the level curve is as informative as for long-acting compounds, but because dose timing set against subjective markers gives signal that is otherwise lost.

Frequently asked questions

What is the Wolverine stack?

The Wolverine stack is a community name for BPC-157 plus TB-500, named after the Marvel character's healing. It is discussed for injury recovery and joint and tendon support. Neither compound is approved; BPC-157's evidence is mostly preclinical and the FDA has no human exposure data for TB-500.12

What is the Glow Protocol?

The Glow Protocol is GHK-Cu, BPC-157 and TB-500 together: the Wolverine Stack plus GHK-Cu, which is linked to skin and collagen in a review whose evidence is largely cosmetic and animal.5

Can I run both at once?

Running all three together is the Glow Protocol. No interaction study of the three was found. The practical considerations are three vials, more injections and higher cost.

How long does the Wolverine stack take to work?

No human trial measured it. Users commonly report less soreness within 1-2 weeks and joint or tendon changes over 4-8 weeks; the research behind BPC-157 is mostly preclinical.1

Which is better for joint pain: Wolverine Stack or Glow Protocol?

For joint pain, the two share the same BPC-157 and TB-500 base, so the Wolverine Stack is the narrower option. BPC-157's preclinical studies covered tendon, ligament and bone injuries, and its one human study was in chronic knee pain; GHK-Cu's evidence is mainly in skin and wound healing.15

References

  1. Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. pubmed.ncbi.nlm.nih.gov
  2. US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026). 2026. fda.gov
  3. He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022. pubmed.ncbi.nlm.nih.gov
  4. Bjørklund G et al. Thymosin β4: a multi-faceted tissue repair stimulating protein in heart injury. Curr Med Chem. 2020. pubmed.ncbi.nlm.nih.gov
  5. Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015. pubmed.ncbi.nlm.nih.gov
  6. Eli Lilly (DailyMed). Humatrope (somatropin) label. 2026. dailymed.nlm.nih.gov
  7. Ferring Pharmaceuticals (DailyMed). Novarel (chorionic gonadotropin) for injection label. 2025. dailymed.nlm.nih.gov
  8. EMD Serono (DailyMed). Serostim (somatropin) label. 2026. dailymed.nlm.nih.gov